LLY|Analyst Targets
LLY|Company Info
LLY|Insider Trading
LLY|Fundamentals
LLY|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $9.96 | - | - |
| Q2'26 | $6.07 | $8.38 | +38.1% |
| Q1'26 | $6.79 | $8.55 | +25.9% |
| Q4'25 | $6.74 | $7.54 | +11.9% |
| Q3'25 | $5.89 | $7.02 | +19.2% |
| Q2'25 | $5.59 | $6.31 | +12.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $22.6B | - | - |
| Q2'26 | $20.9B | $23.0B | +9.8% |
| Q1'26 | $17.8B | $19.8B | +11.1% |
| Q4'25 | $18.1B | $19.3B | +6.4% |
| Q3'25 | - | $17.6B | - |
| Q2'25 | - | $15.6B | - |
LLY|Monthly Returns
Market Data
LLY Stock Snapshot
- Market cap
- 1.10T
- P/E ratio
- 41.1
- Day range
- $1158.35 – $1206.63
- News sentiment
- 70/100 · Bullish
- Analyst target
- $1328.83 (+12.2%)
- Consensus
- Buy · 39 analysts
LLY is in a holding pattern - neither trend nor momentum has taken control. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.
Behaviour On Record
What LLY's own history says about today's numbers
- Realized volatility (21d)
- 17.4% 23rd pct
- Below its peak
- -10.5%
- vs 200-day average
- +6.6%
- Up days (1y)
- 49%
Eli Lilly and Company is currently running 17.4% annualised volatility over the last 21 sessions. Measured against LLY's own 13 years of daily returns rather than a market-wide average, that is the 23rd percentile — unusually subdued by its own history, against a typical reading of 23.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
LLY is trading -10.5% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.0%, and the deepest was -32.6% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +6.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 42nd percentile — close to the gap it normally carries. Over the past year LLY closed higher on 49% of sessions, and it is currently 2 sessions into a rising streak.
On October specifically: over 13 years of records, LLY finished the month higher 8 of 13 times, with a median return of +1.9% and an average of +0.6%. Its strongest month historically has been June at +5.6% on average, its weakest July at -0.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: LLY has opened more than 2% away from the prior close in 71 of 3,268 sessions (2.2% of the time), with the largest gaps running +11.5% and -5.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, LLY moved an average of 3.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.0% and a largest of -6.1%.
All figures computed from 3,269 daily closes between 2013-10-07 and 2026-10-06, split-adjusted, recomputed daily. Percentiles are against LLY's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of LLY's sector?
Eli Lilly and Company sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).
- Sector rank
- #3 of 12
- Sector state
- Lagging
- Sector rotation score
- 64
Analyst Rating Changes
Are analysts turning bullish or bearish on LLY?
Morgan Stanley most recently reiterated its rating on Eli Lilly and Company to Overweight on Oct 7, 2026 with a price target of $1430 (from $1419). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Morgan Stanley — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
LLY Competitive Positioning
- LLYyou're hereEli Lilly and Company$1.10T-0.38%
- AMGNAmgen Inc.$217.9B+0.23%
- AZNAstrazeneca PLC$182.4B-0.01%
- GILDGilead Sciences, Inc.$179.2B+0.02%
- PFEPfizer Inc.$157.1B0.00%
- BMYBristol-Myers Squibb Company$121.2B-0.32%
Held by These ETFs
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Fisher Asset Management, LLC | • Hold | 4,453,062 | 0.48% | $3.40B | 2025-11-12 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Dan Newhouse | House | WA04 | ▼ Sell | $1K - $15K | 2026-07-10 | 2026-07-17 |
| Michael Rulli | House | OH06 | ▼ Sell | $1K - $15K | 2026-07-01 | 2026-08-07 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $50K - $100K | 2026-06-10 | 2026-07-02 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-04-14 | 2026-05-08 |
| Elizabeth Fletcher | House | TX07 | ▼ Sell | $1K - $15K | 2026-04-08 | 2026-05-01 |
| Byron Donalds | House | FL19 | ▲ Buy | $1K - $15K | 2026-04-02 | 2026-05-13 |
| Alan Armstrong | Senate | OK | ▼ Sell | $1K - $15K | 2026-03-27 | 2026-07-21 |
| David J. Taylor | House | OH02 | ▲ Buy | $1K - $15K | 2026-02-26 | 2026-03-06 |
| Angus King | Senate | - | ▼ Sell | $1K - $15K | 2026-02-13 | 2026-03-24 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-02-09 | 2026-02-20 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2026-01-16 | 2026-02-02 |
| Michael Rulli | House | OH06 | ▲ Buy | $1K - $15K | 2026-01-02 | 2026-08-07 |
| Angus King | Senate | - | ▲ Buy | $1K - $15K | 2025-12-29 | 2026-01-26 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-12-18 | 2026-01-15 |
| David J. Taylor | House | OH02 | ▼ Sell | $1K - $15K | 2025-12-10 | 2025-12-19 |
| Michael Rulli | House | OH06 | ▼ Sell | $1K - $15K | 2025-12-02 | 2026-08-07 |
| John Boozman | Senate | AR | ▼ Sell | $1K - $15K | 2025-11-21 | 2026-08-24 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-11-13 | 2025-12-11 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $1K - $15K | 2025-10-24 | 2025-11-04 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| John Boozman | Senate | AR | ▲ Buy | $1K - $15K | 2025-08-22 | 2025-09-12 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-08-14 | 2025-09-11 |
| David J. Taylor | House | OH02 | ▲ Buy | $15K - $50K | 2025-08-14 | 2025-09-02 |
| John Boozman | Senate | AR | ▲ Buy | $1K - $15K | 2025-08-11 | 2025-09-12 |